Skip to main content

Roser Ferrer Costa

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

Roser Ferrer Costa

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Healthcare activity:
Since 2007 I have been working at the University Hospital, where I trained as a specialist in Clinical Biochemistry (2003). I am a trained pharmacist and until 2019 I was responsible for the Hormone Process (Endocrin Pathology) of the same Service and later Head of Section of the Automated Laboratory. Since 2023, I have been Head of Clinical Biochemistry Service.

The Clinical Biochemistry Service is part of the Clinical Laboratories of the Vall d'Hebron University Hospital, which also provides coverage for the entire population, with pubic health care, of the city of Barcelona (1.5 million people).
In 2019 I completed my master's degree in Health Institutions Management, I have training in healthcare processes and specialisation in automation, concepts that I try to apply in my usual practice and in the Service. Finally, I am the secretary of the hospital's In Vitro Diagnostic Commission.

Research activity:
I am a Doctor of Biomedicine from the University of Barcelona (2015) and co-chief of Clinical Biochemistry Group, Vehiculation of Pharmacists and Therapy Research from the Research Institute of the Vall d'Hebron University Hospital since 2023. In recent years I have been actively involved in different publications of the Service itself and in collaboration with research groups and hospital services.
Attached to the eCore Personalized Medicine, Innovative Diagnostics, Molecular Imaging . Digital Health of VHIR.
I am president of the Catalan Clinical Laboratory Science Association (since June 2021) and member of the Hormone Commission (since 2011) and of the Executive Committee (since 2018) of the Spanish Society of Medicine of the Laboratory (SEQCML).

Docent Activity:
I am currently Associate Professor of the Autonomous University of the Department of Biochemistry and Molecular Biology, Medicine Biochemistry Unit.
I am participating in the postgraduate doctoral thesis management of the Biochemistry Service.

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: -
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

RECEPTORES INHBITORIOS (NEGATIVE IMMUNE CHECKPOINT RECEPTORS, NCRs) EN AUTOINMUNIDAD TIROIDEA Y CANCER, NUEVAS VÍAS TERAPÉUTICAS EN AUTOINMUNIDAD

IP: -
Collaborators: Oscar González López, Roser Ferrer Costa, Carmela Iglesias i Felip, Anna Casteras Román, Elena Garralda Cabanas, Daniel Alvarez De la Sierra
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI17/00324
Duration: 01/01/2018 - 30/06/2022

PAPEL DEL RECEPTOR DE TSH EN LOS TIMOCITOS EN EL INICIO DE LA ENFERMEDAD DE GRAVES (EG) Y MECANISMOS DE TIROIDITIS

IP: -
Collaborators: Oscar González López, Roser Ferrer Costa, Gabriel Obiols Alfonso, Anna Casteras Román, Joaquin Fernandez Doblas
Funding agency: Instituto de Salud Carlos III
Funding: 80465
Reference: PI14/00848
Duration: 01/01/2015 - 31/12/2018

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Inca Vilar Sastre

Inca Vilar Sastre

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Cristina Prat Vidal

Cristina Prat Vidal

Research assistant
Transfusional Medicine
Read more
Shilena Narci Rodriguez

Shilena Narci Rodriguez

Infectious Diseases
Read more
Marina Llanas Martinez

Marina Llanas Martinez

Predoctoral researcher
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.